دورية أكاديمية
Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
| العنوان: | Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy. |
|---|---|
| المؤلفون: | van Erning FN; Department of Research, Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands.; Department of Public Health, Erasmus MC, Rotterdam, The Netherlands., Janssen-Heijnen ML; Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands.; Department of Epidemiology, Maastricht UMC, GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands., Creemers GJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Pruijt JF; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Maas HA; Department of Geriatric Medicine, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands., Lemmens VE; Department of Research, Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands.; Department of Public Health, Erasmus MC, Rotterdam, The Netherlands. |
| المصدر: | International journal of cancer [Int J Cancer] 2017 Jan 01; Vol. 140 (1), pp. 224-233. Date of Electronic Publication: 2016 Sep 22. |
| نوع المنشور: | Comparative Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1995- : New York, NY : Wiley-Liss Original Publication: 1966-1984 : Genève : International Union Against Cancer |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Capecitabine/*administration & dosage , Colorectal Neoplasms/*drug therapy , Colorectal Neoplasms/*pathology , Organoplatinum Compounds/*administration & dosage, Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Capecitabine/therapeutic use ; Colorectal Neoplasms/surgery ; Disease-Free Survival ; Female ; Humans ; Male ; Neoplasm Staging ; Organoplatinum Compounds/therapeutic use ; Oxaliplatin ; Treatment Outcome |
| مستخلص: | The aim of this study is to investigate the effects of CAPOX and capecitabine on recurrence-free survival (RFS) and overall survival (OS) among elderly stage III colon cancer patients and to evaluate the effect of (non-)completion. Patients aged ≥70 years who underwent resection only or who were subsequently treated with CAPOX or capecitabine in 10 large non-academic hospitals were included. RFS and OS were analyzed with Kaplan-Meier curves and multivariable Cox regression adjusted for patient and tumor characteristics. 982 patients were included: 630 underwent surgery only, 191 received CAPOX and 161 received capecitabine. Five-year RFS and OS did not differ between capecitabine and CAPOX (RFS: 63% vs. 60% (p = 0.91), adjusted HR = 0.99 (95%CI 0.68-1.44); OS: 66% vs. 66% (p = 0.76), adjusted HR = 0.93 (95%CI 0.64-1.34)). After resection only, RFS was 38% and OS 37%. Completion rates were 48% for CAPOX and 68% for capecitabine. Three-year RFS and OS did not differ between patients who discontinued CAPOX early and patients who completed treatment with CAPOX (RFS: 61% vs. 69% (p = 0.21), adjusted HR = 1.42 (95%CI 0.85-2.37); OS: 68% vs. 78% (p = 0.41), adjusted HR = 1.17 (95%CI 0.70-1.97)). Three-year RFS and OS differed between patients who discontinued capecitabine early and patients who completed treatment with capecitabine (RFS: 54% vs. 72% (p = 0.01), adjusted HR = 2.07 (95%CI 1.11-3.84); OS: 65% vs. 80% (p = 0.01), adjusted HR = 2.00 (95%CI 1.12-3.59)). Receipt of CAPOX or capecitabine is associated with improved RFS and OS. The advantage does not differ by regimen. The addition of oxaliplatin might not be justified in elderly stage III colon cancer patients. (© 2016 UICC.) |
| فهرسة مساهمة: | Keywords: adjuvant chemotherapy; capecitabine; colon cancer; elderly; overall survival; oxaliplatin; recurrence-free survival |
| المشرفين على المادة: | 0 (Organoplatinum Compounds) 04ZR38536J (Oxaliplatin) 6804DJ8Z9U (Capecitabine) |
| تواريخ الأحداث: | Date Created: 20160913 Date Completed: 20170508 Latest Revision: 20181202 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1002/ijc.30423 |
| PMID: | 27615021 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!